Topic

Articles

Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to a new study.

TKI Leads to Superior Outcomes in ALL With an ABL-Class Fusion, Study Says

Proteasome inhibitors have brought major advances in the treatment of multiple myeloma (MM), but eventual drug resistance remains a serious hurdle.



Review Updates Mechanisms Underlying Proteasome Inhibitor Resistance in MM

Data from the EMPOWER-Lung 1 trial of cemiplimab (Libtayo) monotherapy vs chemotherapy show why the fully-human monoclonal antibody could become a new treatment option for non–small cell lung cancer (NSCLC).

Phase 3 Trial Results Highlight Cemiplimab’s Potential in NSCLC

Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.

Comparing Disease Impact and Activity in Psoriatic Arthritis by Ethnic Background

Videos

Relapse at an older age can significantly contribute to a worsening of multiple sclerosis (MS), explained Burcu Zeyda, MD, assistant professor of neurology, assistant professor of radiology, at Mayo Clinic.

Dr Burcu Zeydan Discusses How, Why Postrelapse Recovery Potential Declines With Older Age in MS

In individuals with type 2 diabetes with no previous insulin treatment, once-weekly injections of insulin icodec resulted in glucose-lowering efficacy and a safety profile similar to individuals who took once-daily insulin glargine U100. 

Phase 2 Trial Shows Weekly Insulin Injection Outcomes Similar to Daily Injections for T2D

FDA will review the first chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of multiple myeloma (MM) in adults who have not responded or have relapsed after at least 3 other therapies.

FDA Accepts Anti-BCMA Ide-cel for MM for Priority Review

The KRAS mutation occurs in 13% of non–small cell lung cancers (NSCLC) and leads to worse outcomes in NSCLC.

Sotorasib Shows Benefit for Patients With Certain Type of NSCLC

A new analysis of ADAURA data shows osimertinib cuts the risk of brain metastases or death by 82% compared with placebo in certain early-stage patients with NSCLC.

Osimertinib Sharply Cuts Risk of Brain Metastases After Surgery in EGFR-Mutated NSCLC

Both neurofibromatosis type 1 (NF1) and Tuberous Sclerosis Complex (TSC) share similar types of manifestations; researchers hypothesized that the tool would be useful for NF1 in addition to TSC.

Clinical

New content coming soon, please check back later.